You are here: Home » PTI Stories » National » News
Business Standard

Eris Lifesciences raises Rs 779 crore from anchor investors

Press Trust of India  |  New Delhi 

Eris Lifesciences today mopped up Rs 779 crore from 21 anchor investors, including Investment Authority and

Ahead of its initial public offer starting tomorrow, the company has allotted 1.29 crore at a price of Rs 603 apiece.



The price band for the share sale has been fixed at Rs 600-603.

According to a filing by the company to the exchanges, it has raised Rs 779.43 crore by allotting to 21 anchor investors.

The anchor investors include Investment Authority - Behave, India, Morgan Stanley Investment Fund Inc, Magnum Balanced Fund, FIL (Mauritius) Ltd, Merrill Lynch Markets Pte Ltd and

The offer, which closes on June 20, comprises sale of 2.89 crore

The book Running Lead Managers to the offer are Axis Capital, Citigroup and Credit Suisse Securities (India).

Eris Lifesciences is into manufacturing of branded pharmaceutical products in select therapeutic areas.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Eris Lifesciences raises Rs 779 crore from anchor investors

Eris Lifesciences today mopped up Rs 779 crore from 21 anchor investors, including Abu Dhabi Investment Authority and Goldman Sachs. Ahead of its initial public offer starting tomorrow, the company has allotted 1.29 crore shares at a price of Rs 603 apiece. The price band for the share sale has been fixed at Rs 600-603. According to a filing by the company to the exchanges, it has raised Rs 779.43 crore by allotting shares to 21 anchor investors. The anchor investors include Abu Dhabi Investment Authority - Behave, Goldman Sachs India, Morgan Stanley India Investment Fund Inc, SBI Magnum Balanced Fund, FIL Investments (Mauritius) Ltd, Merrill Lynch Markets Singapore Pte Ltd and IDFC Premier Equity Fund. The offer, which closes on June 20, comprises sale of 2.89 crore shares. The book Running Lead Managers to the offer are Axis Capital, Citigroup Global Markets India and Credit Suisse Securities (India). Eris Lifesciences is into manufacturing of ... Eris Lifesciences today mopped up Rs 779 crore from 21 anchor investors, including Investment Authority and

Ahead of its initial public offer starting tomorrow, the company has allotted 1.29 crore at a price of Rs 603 apiece.

The price band for the share sale has been fixed at Rs 600-603.

According to a filing by the company to the exchanges, it has raised Rs 779.43 crore by allotting to 21 anchor investors.

The anchor investors include Investment Authority - Behave, India, Morgan Stanley Investment Fund Inc, Magnum Balanced Fund, FIL (Mauritius) Ltd, Merrill Lynch Markets Pte Ltd and

The offer, which closes on June 20, comprises sale of 2.89 crore

The book Running Lead Managers to the offer are Axis Capital, Citigroup and Credit Suisse Securities (India).

Eris Lifesciences is into manufacturing of branded pharmaceutical products in select therapeutic areas.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Eris Lifesciences raises Rs 779 crore from anchor investors

Eris Lifesciences today mopped up Rs 779 crore from 21 anchor investors, including Investment Authority and

Ahead of its initial public offer starting tomorrow, the company has allotted 1.29 crore at a price of Rs 603 apiece.

The price band for the share sale has been fixed at Rs 600-603.

According to a filing by the company to the exchanges, it has raised Rs 779.43 crore by allotting to 21 anchor investors.

The anchor investors include Investment Authority - Behave, India, Morgan Stanley Investment Fund Inc, Magnum Balanced Fund, FIL (Mauritius) Ltd, Merrill Lynch Markets Pte Ltd and

The offer, which closes on June 20, comprises sale of 2.89 crore

The book Running Lead Managers to the offer are Axis Capital, Citigroup and Credit Suisse Securities (India).

Eris Lifesciences is into manufacturing of branded pharmaceutical products in select therapeutic areas.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22